Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Chemotherapeutics in the treatment of multiple sclerosis.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Antioxidant properties of the triaminopyridine, flupirtine.
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Repurposing drugs for disease modification in multiple sclerosis
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

Pages